FDA designates raludotatug deruxtecan as a breakthrough therapy for treating platinum-resistant ovarian cancers, enhancing ...

During a live event, Shirish M. Gadgeel, MD, discussed different management approaches to the improve tolerability of ...

The COCOON study reveals a new dermatology management strategy that significantly reduces skin-related adverse effects in ...

During a live event, Tian Zhang, MD, MHS, discussed darolutamide in mHSPC, with efficacy and cost being key considerations for treatment selection.

A phase 2 study reveals autologous TIL therapy's potential to stabilize recurrent head and neck cancer, offering hope for improved treatment options.

New 5-year data reveals cemiplimab plus chemotherapy significantly enhances survival rates for advanced non-small cell lung cancer patients.

Combination therapy of casdatifan and cabozantinib shows promising efficacy and manageable safety in advanced clear cell ...

FDA accepts relacorilant and nab-paclitaxel for platinum-resistant ovarian cancer, showing promising survival benefits in ...

FDA fast tracks GLSI-100 for HER2-positive breast cancer, promising new hope for patients with unmet medical needs. Discover ...

During a live event, Neil M. Iyengar, MD, discusses NCCN guidelines and NATALEE trial data for using CDK4/6 inhibitors like ...

Promising results emerge from a clinical trial combining IDE397 and sacituzumab govitecan for treating MTAP-deleted ...

Rezatapopt shows promising efficacy in treating various tumors with TP53 Y220C mutations, highlighting its potential as a ...